Acellular pertussis vaccine composed of genetically inactivated pertussis toxin: Safety and immunogenicity in 12- to 24- and 2- to 4-month-old children

This publication has 13 references indexed in Scilit:

• Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial
  Vaccine, 1990
• Metabolic, humoral, and cellular responses in adult volunteers immunized with the genetically inactivated pertussis toxin mutant PT-9K/129G.
  The Journal of Experimental Medicine, 1990
• Haemophilus influenzae infections and whooping cough
  The Lancet, 1990
• Immunogenicity and safety of a pertussis vaccine composed of pertussis toxin inactivated by hydrogen peroxide, in 18- to 23-month-old children
  The Journal of Pediatrics, 1990
• 'Pertussis Vaccine Encephalopathy': It Is Time to Recognize It as the Myth That It Is
  JAMA, 1990
• Mutants of Pertussis Toxin Suitable for Vaccine Development
  Science, 1989
• Mortality and morbidity from invasive bacterial infections during a clinical trial of acellular pertussis vaccines in Sweden
  The Pediatric Infectious Disease Journal, 1988
• PLACEBO-CONTROLLED TRIAL OF TWO ACELLULAR PERTUSSIS VACCINES IN SWEDEN—PROTECIVE EFFICACY AND ADVERSE EVENTS
  The Lancet, 1988
• Acellular pertussis vaccine in adults: Adverse reactions and immune response
  European Journal of Clinical Microbiology & Infectious Diseases, 1987
• DEVELOPMENT OF A PERTUSSIS COMPONENT VACCINE IN JAPAN
  The Lancet, 1984